Please provide your email address to receive an email when new articles are posted on . The rare and complex Behcet’s disease is often misdiagnosed or undiagnosed, leading to significant, but ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
InvestorsHub on MSN
Soligenix shares jump on encouraging data for Behçet’s disease therapy
Soligenix Inc (NASDAQ:SNGX) shares rose 5.2% on Thursday after the company released positive findings from a Phase 2a ...
DESTIN, Fla. — Behçet syndrome — which is classified as a vasculitis — is marked by distinct features that differentiate it from other autoimmune and autoinflammatory diseases, according to Yusuf ...
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
Clinical Trials Arena on MSN
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet's disease. The proof-of-concept study examined SGX945 for treating oral ulcers in the ...
PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback